More than 2,100 pregnant Colombian women are infected with the mosquito-borne Zika virus, the country’s national health institute said on Saturday, as the disease continues its spread across the Americas.

The virus has been linked to the devastating birth defect microcephaly, which prevents fetus’ brains from developing properly. There is no vaccine or treatment.

There are 20,297 confirmed cases of the disease in Colombia, the national health institute said in a epidemiology bulletin, among them 2,116 pregnant women.

There are so far no reported cases of microcephaly or deaths from the virus in Colombia.

The institute said 37.2 percent of pregnant women with Zika live in Norte de Santander province, along the eastern border with Venezuela.

Earlier figures from the health ministry showed 560 pregnant women had the disease, out of more than 13,500 infections.

Zika cases have been confirmed in 23 countries and territories in the Americas and scientists are racing to develop a vaccine for the virus.

Nearly half of Colombia’s Zika cases have been reported in the country’s Caribbean region, the bulletin said. More than 60 percent of those infected are women.

The health ministry has said Zika infection falls within the health requirements women must meet to get abortions in the country, which restricts the procedure unless patients are victims of rape, have significant medical problems or the fetus is fatally deformed.

Many women, especially those living far from large cities, struggle to find abortion providers even when they meet the legal requirements and illegal abortions are widespread.

The government has urged women to delay pregnancy for six to eight months to avoid potential infection. Officials expect up to 700,000 cases.

Brazil is the country hit hardest by the disease. It has reported around 3,700 cases of microcephaly strongly suspected to be related to Zika.

The World Health Organization has said as many as 4 million people in the Americas may become infected.

(Reporting by Julia Symmes Cobb; Editing by Meredith Mazzilli)

Visit the Source Site

Powered by WPeMatico

Last January, long lines formed outside health clinics in Recife, a city in Brazil’s northeast hit hard in recent years by outbreaks of dengue, a painful tropical disease.

Doctors were on guard because federal health officials and the World Health Organization (WHO) had warned 2015 would be a bad year for dengue and possibly another viral disease, chikungunya, both spread by the same type of mosquito.

But the symptoms of the hundreds of people seeking treatment did not fit dengue. Instead of high fevers and intense muscular aches that dengue is known to cause, patients were running only slight temperatures and complaining of joint pain. Many had rashes sooner than with dengue and chikungunya.

“We knew this was something else,” says Carlos Brito, a doctor from Recife who told state and federal health authorities in January-February last year that they were wrong to classify all the cases as dengue. “But the authorities were slow to believe,” he said.

Kleber Luz, a physician in Natal, a city 300 km up the Atlantic coast, says he gave similar feedback but got the same response. The two – who were part of a group of doctors discussing the odd symptoms in text messages – grew frustrated with the authorities’ narrow focus. They asked the federal health ministry to broaden its search beyond viruses known in the area.

It took until early May for the health ministry to recognize that the Zika virus had arrived in Brazil and to alert the WHO’s regional arm, the Washington-based Pan American Health Organization. And it wasn’t until November that a Rio de Janeiro laboratory made a link between the virus and microcephaly, which can lead to abnormally small brains in developing babies.

    The WHO has been lambasted in the past couple of years by scientists, aid organizations, and public health experts for the slow way in which it initially reacted to the Ebola epidemic as it spread across West Africa in 2014. And so far, the hesitant response to the Zika outbreak, which has created the worst global health scare since Ebola, says much about the difficulties that the WHO and other health authorities face in combating unexpected public health threats.

EXPLODING ACROSS THE REGION

On Dec. 1, the WHO cited the lab evidence linking Zika to microcephaly in an advisory to its member countries. It will consider on Monday whether to declare an international emergency.

    The WHO said in Geneva on Thursday that Zika in the last few months has spread “explosively” to more than 20 other countries in the Americas and could infect as many as 4 million people.

Whether the health authorities in Brazil and the leadership at the WHO have taken too long to get to this point is a subject of debate within the international health community.

The Brazilian government says its response when it was first alerted by the doctors about the unusual symptoms they were seeing was driven by the evidence.

“It was too early,” said Claudio Maierovitch, director of the health ministry’s Department of Communicable Disease Surveillance. “There are so many other viral possibilities and Zika had never been seen in this hemisphere.”

    And he said that when Zika was identified, the authorities’ response was based on knowledge of the disease. Previous outbreaks  of Zika, a virus first identified in 1947 in Uganda, had occurred in small and scattered rural populations in Africa and Southeast Asia and the symptoms were relatively benign.  

“We based our response on the scientific knowledge available, that Zika caused a mild illness without major complications,” said Maierovitch. “But as soon as we saw that there was an association with microcephaly, we reacted in record time.”

Critics say that the WHO has been slow to act after the link between Zika and microcephaly was made, and should have declared an emergency as soon as that was determined. “My chief criticism is of WHO in Geneva. After being widely condemned for acting late on Ebola, it is now sitting back with Zika,” said Lawrence O. Gostin, a professor of public health law at Georgetown University, who has worked with the WHO and written extensively about pandemics and policy. 

WHO officials say the agency’s response to Zika is driven by science, and they point out that much remains unclear, including the precise nature of any link between Zika and microcephaly.

    “In any unfolding crisis you’re dealing with a lot of uncertainty,” Bruce Aylward, the WHO’s assistant director-general, told reporters on Thursday.

Since October, 4,180 cases of microcephaly have been reported in Brazil but only 270 have so far been confirmed, with just six so far linked by the government to Zika. Of the rest, 3,448 are still being investigated through a long process involving clinical research, laboratory testing and monitoring of the infants’ development, and 462 were dismissed as not being microcephaly.

Following the spread of the disease is difficult. Many of those who get Zika can recover quickly from only mild symptoms, and across the Americas, hospitals do not have the clinical testing materials to quickly and definitively determine whether a patient is infected.

     “I THINK IT’S ZIKA”

     Luz, the Natal doctor, may have been the first person to make a link between the symptoms his patients had shown and Zika.

    After poring over scientific literature about a 2013 outbreak in French Polynesia, Luz in early March sent a text to a WhatsApp group for doctors, declaring: “I think it’s Zika.” He compared the symptoms he had seen with those reported in that outbreak.

Soon, several doctors in the same region began collecting blood samples from patients and sent them to various laboratories for analysis. On April 30, a laboratory at the Federal University of Bahia, also in Brazil’s northeast, said it had identified the presence of Zika in samples from one patient.

    The health ministry alerted state governments.

    On May 2, it notified PAHO. The notification put a Zika outbreak on record at the WHO.

    On May 7, PAHO issued an “epidemiological alert” saying “public health authorities of Brazil are investigating a possible transmission of the Zika virus.”

    But concern remained limited mostly to the contagiousness of Zika, rather than whether it could be a serious threat. In its alert, PAHO wrote: “Complications (neurological, autoimmune) are rare.”

    ‘REAL ANGUISH’

    In late May, Brito received a call from a Recife neurologist who noticed a surge of new patients with symptoms of Guillain-Barré, a little-understood autoimmune syndrome that can weaken the muscles and cause paralysis.

Brito interviewed the patients, many of whom said they had previously suffered a light fever, joint pain and rashes. He collected blood samples and by June a laboratory had used genetic testing to find traces of the Zika virus.

“It was real anguish,” Brito said of the patient’s suffering and the wait for official confirmation of Zika’s presence.

But despite the results, there was no proof to show that it was Zika causing the syndrome. Neither the Brazilian health ministry nor PAHO heightened warnings.

    By September, the chat groups among doctors were abuzz over a spike in the number of babies born with microcephaly.

    Many mothers of affected babies recalled having Zika-type symptoms.

    In October, Adriana Melo, an obstetrician in the nearby state of Paraiba, noticed troubling signs in sonograms of a 34-year-old expectant mother.

    There were calcium deposits in the developing baby’s brain, a possible sign of viral infection. The cerebellum, the part of the brain crucial for motor control, was shrinking.

    Melo phoned the Oswaldo Cruz Foundation, a public health institute in Rio de Janeiro, and got a lab there to test the patient’s amniotic fluid.

    By then, the number of babies born with microcephaly was surging. The health ministry, now more alarmed, declared a national emergency on Nov. 11 and in public comments mentioned that there were possible ties between the condition and Zika.

    The WHO was not yet ready to draw the same parallels.

    On November 17, the Rio lab said it had found the virus in the amniotic fluid. On Nov. 28, after lab tests from another baby, Brazil’s government confirmed the link between the virus and microcephaly.

    Starting Nov. 30, WHO deployed a small team of researchers from PAHO’s Washington headquarters to Brazil.

    On December 1, PAHO issued a new advisory,  warning countries in the region of the link between the virus and microcephaly. Two months later, the WHO is considering whether to declare an international emergency.

    “You have to gather the data,” says Marcos Espinal, director of the department of communicable diseases at PAHO, dismissing criticism that the regional body or headquarters could have moved any sooner.

(Additional reporting by Anthony Boadle, Brad Brooks, Stephanie Nebehay, Tom Miles and Julie Steenhuysen; Editing by Kieran Murray, Lisa Girion and Martin Howell)

Sueli Maria (obscured) holds her seven-day-old daughter Milena, who has microcephaly, at a hospital in Recife, Brazil, January 28, 2016.

Reuters/Ueslei Marcelino

Visit the Source Site

Powered by WPeMatico

Companies and scientists are racing to create a Zika vaccine as concern grows over the mosquito-borne virus that has been linked to severe birth defects and is spreading quickly through the Americas.

Zika is now present in 23 countries and territories in the Americas. Brazil, the hardest-hit country, has reported around 3,700 cases of the devastating birth defect called microcephaly that are strongly suspected to be related to Zika.

The Geneva-based World Health Organization (WHO), stung by criticism that it reacted too slowly to West Africa’s Ebola epidemic, convenes an emergency meeting on Monday to help determine its response to the spread of the virus.

The U.S. Centers for Disease Control and Prevention has activated an emergency operations center staffed around the clock to address Zika, agency officials told Reuters.

On Thursday, the WHO said as many as 4 million people in the Americas may become infected by Zika, adding urgency to the research efforts. Vaccine developers made clear a vaccine for widespread public use is at least months, if not years, away.

The closest prospect may be from a consortium including drugmaker Inovio Pharmaceuticals Inc (INO.O) that could have a vaccine ready for emergency use before year-end, according to one of its lead developers. Inovio’s share price gained more than 15 percent in Friday trading.

Canadian scientist Gary Kobinger told Reuters on Thursday the first stage of testing on humans could begin as early as August. If successful, the vaccine might be used during a public health emergency by October or November, said Kobinger, who helped develop a trial vaccine for the Ebola virus.

Privately owned vaccine developer Hawaii Biotech Inc said it began a formal program to test a Zika vaccine last fall as the virus started to gain traction in Brazil, although it has no timetable yet for clinical trials.

“Right now, we are in the pre-clinical stage, as I suspect everyone is,” Chief Executive Officer Dr. Elliot Parks told Reuters.

Another private vaccine developer, Boston-based Replikins Ltd, said it was preparing to start animal studies on a Zika vaccine in the next 10 days. Data from the trials on mice and rabbits would likely be out in the next couple of months, Replikins Chairman Samuel Bogoch told Reuters.

“No one has the $500 million on hand to take it (a vaccine) all the way to human trials. Somewhere along the course we hope to have big pockets join us,” Bogoch said.

‘FIGHT THE MOSQUITO’

Zika had been viewed as a relatively mild illness until Brazilian health officials identified it as a matter of concern for pregnant women. While a direct causal relationship has not been established, scientists strongly suspect a link between Zika and thousands of children born in Brazil with abnormally small heads, brain defects and impaired vision.

There is no treatment for Zika infection.

Efforts to combat Zika are focused on protecting people from being bitten and on eradicating mosquitoes, a tough task in many parts of Latin America, where people live in poverty and there are plentiful breeding grounds for the insect.

“We do not have a vaccine for Zika yet. The only thing we can do is fight the mosquito,” Brazilian President Dilma Rousseff said on Friday, reiterating her call for a national eradication effort.

Rousseff said tests for the development of a vaccine would begin next week at the Butantan Institute, one of Brazil’s leading biomedical research centers in Sao Paulo.

U.S. President Barack Obama spoke on Friday with Rousseff about the spread of the virus, the White House said.

“The leaders agreed on the importance of collaborative efforts to deepen our knowledge, advance research and accelerate work to develop better vaccines and other technologies to control the virus,” the White House said in a statement.

Zika has hit Brazil just as it prepares to host the Olympic Games in Rio de Janeiro on Aug. 5-21, an event that draws hundreds of thousands of athletes, team officials and spectators. The International Olympic Committee (IOC) assured teams on Friday the Olympics would be safe from Zika, but urged visitors to carefully protect themselves.

U.S. lawmakers have begun to press the Obama administration for details of its response to Zika. At least 31 people in the country have been infected, all of them after travel to affected countries.

The U.S. Senate Health, Education, Labor and Pensions Committee is planning a hearing on Zika “very soon,” said Republican Senator Lamar Alexander of Tennessee, who called the threat posed by the virus to the United States a “big concern.”

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Disease, said he did not expect the United States to be hit hard like other some countries in South America and the Caribbean.

“We prepare for the possibility of a major outbreak but we believe it is unlikely to happen,” Fauci said.

(Reporting by Rod Nickel in Winnipeg, Manitoba; and Natalie Grover in Bengaluru; Additional reporting by Amrutha Penumudi in Bengaluru; Julie Steenhuysen in Chicago, Toni Clarke in Washington, Karolos Grohmann in Berlin, Anthony Boadle in Brasilia, Jeffrey Dastin in New York; Writing by Frances Kerry; Editing by Will Dunham and Lisa Shumaker)

Visit the Source Site

Powered by WPeMatico